Trial Profile

A Phase 1/2 Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ABO-101 in Participants With Primary Hyperoxaluria Type 1 (PH1)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 29 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

22 May 2025 Planned initiation date changed from 1 Apr 2025 to 1 Jun 2025.
28 Apr 2025 According to an Arbor Biotechnologies media release, In an oral session, Arbor will showcase data supporting the therapeutic potential of ABO-101 for the treatment of primary hyperoxaluria type 1 (PH1) and its clinical evaluation in the redePHine clinical study at the 2025 American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
02 Apr 2025 Planned initiation date (estimated date of first participant enrollment) changed from 1 Mar 2025 to 1 Apr 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com